Online citations, reference lists, and bibliographies.

Proton Pump Inhibitor Use In Hospitalized Patients: Is Overutilization Becoming A Problem?

C. Durand, Kristine C. Willett, Alicia R. Desilets
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Proton pump inhibitors (PPIs) are among the most common classes of medications prescribed. Though they were previously thought of as safe, recent literature has shown risks associated with their use including increased risk for Clostridium difficile infection, pneumonia, and fractures. Due to these risks, it is important to determine if PPIs are being used appropriately. This review evaluates seven studies in hospitalized patients. Additionally, this review evaluates literature pertaining to recently discovered adverse reactions; all studies found PPIs are being overutilized. Findings highlight the importance of evaluating appropriate therapy with these agents and recommending discontinuation if a proper indication does not exist.
This paper references
10.1016/S0140-6736(09)61525-7
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
M. O'donoghue (2009)
10.1016/j.phrs.2008.09.016
Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety.
V. Savarino (2009)
10.1038/ajg.2011.480
Management of Patients With Ulcer Bleeding
L. Laine (2012)
10.1001/ARCHINTE.167.9.950
Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study.
S. Gulmez (2007)
10.3949/ccjm.77a.10087
Proton pump inhibitor side effects and drug interactions: Much ado about nothing?
Ryan D. Madanick (2011)
Product information. Dexilant (dexlansoprazole)
(2012)
Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAIDrelated ulcer complications
FL Lanza (2009)
10.1007/s00228-010-0871-9
Appropriateness of treatment recommendations for PPI in hospital discharge letters
D. Ahrens (2010)
10.1345/aph.1D129
Impact of Stress Ulcer Prophylaxis Algorithm Study
Christian J Coursol (2005)
10.1001/archinternmed.2010.94
Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.
S. Gray (2010)
Product information. Prevacid (lansoprazole)
(2012)
Drug Safety Communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs)
Fda (2012)
10.1007/s00228-008-0538-y
Proton pump inhibitors: an update of their clinical use and pharmacokinetics
S. Shi (2008)
10.2217/pgs.11.4
Update on the pharmacogenomics of proton pump inhibitors.
K. Hagymási (2011)
Communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs)
FDA Drug Safet (2012)
10.1038/ajg.2009.115
Guidelines for Prevention of NSAID-Related Ulcer Complications
F. Lanza (2009)
10.1093/qjmed/hcq019
Inappropriate utilization of intravenous proton pump inhibitors in hospital practice--a prospective study of the extent of the problem and predictive factors.
Darren G N Craig (2010)
10.1111/j.1572-0241.2007.01275.x
Systematic Review of the Risk of Enteric Infection in Patients Taking Acid Suppression
J. Leonard (2007)
10.1001/jama.2009.261
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.
P. Ho (2009)
10.1016/j.bpg.2010.09.004
Short and long-term PPI treatment for GERD. Do we need more-potent anti-secretory drugs?
S Bruley des Varannes (2010)
10.1046/j.1365-2036.1996.27169000.x
Effect of short‐ and long‐term treatment with omeprazole on the absorption and serum levels of cobalamin
B. Schenk (1996)
10.1177/0115426507022003286
Calcium supplementation in clinical practice: a review of forms, doses, and indications.
Deborah A Straub (2007)
10.3109/00365529109037018
Prophylaxis of gastrointestinal tract bleeding with magaldrate in patients admitted to a general hospital ward.
R. Estruch (1991)
10.1161/CIRCULATIONAHA.109.873497
Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome
J. Rassen (2009)
10.1001/archinternmed.2010.34
Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor.
K. Stockl (2010)
10.1097/00001610-199607000-00008
Prevacid (lansoprazole).
D. Claussen (1996)
10.1016/j.jcrc.2007.11.003
Do proton-pump inhibitors increase the risk for nosocomial pneumonia in a medical intensive care unit?
M. Beaulieu (2008)
10.1097/SMJ.0b013e3181ce0e7a
Overuse of Acid Suppression Therapy in Hospitalized Patients
R. Gupta (2010)
Product information Aciphex (rabeprazole)
(2012)
10.1007/s11096-006-9028-4
Continuation of Proton Pump Inhibitors from Hospital to Community
K. Grant (2006)
Safety of the longterm use of proton pump inhibitors
AB Thomson (2010)
10.1053/j.gastro.2008.08.045
American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease.
P. Kahrilas (2008)
10.1007/s00223-006-0021-7
Proton Pump Inhibitors, Histamine H2 Receptor Antagonists, and Other Antacid Medications and the Risk of Fracture
P. Vestergaard (2006)
10.1002/jhm.1901
Inappropriate prescribing of proton pump inhibitors in hospitalized patients.
Mark Reid (2012)
Dexilant (dexlansoprazole)
10.1001/jama.2009.722
Acid-suppressive medication use and the risk for hospital-acquired pneumonia.
S. Herzig (2009)
10.1111/j.1365-2036.2005.02454.x
Long‐term use of acid suppression started inappropriately during hospitalization
D. A. Zink (2005)
10.1001/archinternmed.2010.89
Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection.
M. Howell (2010)
10.1056/NEJMoa1007964
Clopidogrel with or without omeprazole in coronary artery disease.
Deepak L. Bhatt (2010)
Prescribing Information. Plavix (clopidogrel) Bridgewater, NJ: Bristol- Myers Squibb/Sanofi Pharmaceuticals Partnership
(2011)
ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998.
(1999)
10.1007/s10620-010-1560-3
Adverse Effects of Long-Term Proton Pump Inhibitor Therapy
E. Sheen (2010)
10.1111/j.1572-0241.2006.00839.x
Magnitude and Economic Impact of Inappropriate Use of Stress Ulcer Prophylaxis in Non-ICU Hospitalized Patients
J. Heidelbaugh (2006)
10.7326/0003-4819-66-5-917
The absorption of calcium carbonate.
P. Ivanovich (1967)
10.1001/JAMA.296.24.2947
Long-term proton pump inhibitor therapy and risk of hip fracture.
Yu-Xiao Yang (2006)
10.1111/j.1365-2753.2012.01838.x
Stress ulcer prophylaxis in non-critically ill patients: a prospective evaluation of current practice in a general surgery department.
Coraline Bez (2013)
10.1001/JAMA.292.16.1955
Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs.
R. Laheij (2004)
Use of acidsuppressive drugs and risk of pneumonia: A systematic review and meta-analysis
CS Eom (2011)
10.3748/WJG.V16.I19.2323
Safety of the long-term use of proton pump inhibitors.
A. Thomson (2010)
Product information. Prilosec (omeprazole)
(2012)
Product information Protonix (pantoprazole)
(2011)
10.18553/JMCP.2010.16.2.122
Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization.
L. Thomas (2010)
Protonix (pantoprazole)
10.1097/00001610-200003000-00011
Aciphex (rabeprazole).
D W Claussen (2000)
10.1093/ajhp/56.4.347
ASHP therapeutic guidelines on stress ulcer prophylaxis
T. A. Armstrong (1999)
10.1038/ajg.2010.445
ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
N. Abraham (2010)
10.2146/AJHP060393
Stress ulcer prophylaxis in hospitalized patients not in intensive care units.
Rebekah R Arthur Grube (2007)
10.1111/j.1365-2036.2010.04284.x
Meta‐analysis: proton pump inhibitor use and the risk of community‐acquired pneumonia
J. Johnstone (2010)
10.1503/cmaj.071330
Use of proton pump inhibitors and risk of osteoporosis-related fractures
L. Targownik (2008)
Prilosec (omeprazole)
10.1503/cmaj.092129
Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis
Chun-Sick Eom (2011)
Product information. Nexium (esomeprazole)
(2012)
10.1097/00001610-199409000-00015
Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group.
D. Cook (1994)
10.1001/archinternmed.2010.51
Proton pump inhibitors for prophylaxis of nosocomial upper gastrointestinal tract bleeding: effect of standardized guidelines on prescribing practice.
P. Yachimski (2010)
10.1345/aph.1G703
Acid Suppressive Therapy Use on an Inpatient Internal Medicine Service
C. Pham (2006)
10.1345/aph.1P425
Esomeprazole but Not Pantoprazole is Associated with Lower Plasma Concentrations of Clopidogrel's Active Metabolite
Ankie M. Harmsze (2011)
Clinical Medicine Insights: Gastroenterology
10.7326/0003-4819-152-6-201003160-00003
Outcomes With Concurrent Use of Clopidogrel and Proton-Pump Inhibitors
W. Ray (2010)
Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership
(2011)
10.1111/J.1365-2753.2006.00742.X
Stress ulcer prophylaxis for non-critically ill patients on a teaching service.
K. O. Hwang (2007)
Reducing the cost of proton pump inhibitors by adopting best practice.
J. Hughes (2009)
Nexium (esomeprazole)
10.18553/JMCP.2010.16.2.114
Descriptive analysis of a clinical pharmacy intervention to improve the appropriate use of stress ulcer prophylaxis in a hospital infectious disease ward.
H. Khalili (2010)



This paper is referenced by
10.1371/journal.pone.0204231
Duration and dosing of Proton Pump Inhibitors associated with high incidence of chronic kidney disease in population-based cohort
Antonio Rodríguez-Poncelas (2018)
10.2147/CIA.S190983
Comparison of three criteria for potentially inappropriate medications in Chinese older adults
Zhuo Ma (2019)
10.1002/phar.1801
Risk and Severity of Hospital-Acquired Clostridium difficile Infection in Patients Taking Proton Pump Inhibitors.
Paul O. Lewis (2016)
10.3177/JNSV.62.330
Effect of Long-Term Proton Pump Inhibitor Therapy on Nutritional Status in Elderly Hospitalized Patients.
Mariko Nakamichi (2016)
10.4103/jrpp.JRPP_18_79
Prescribing Pattern of Proton Pump Inhibitors in Qatar Rehabilitation Institute: A Retrospective Study
Lama Madi (2019)
10.1016/j.ekir.2018.10.023
Increased Proton Pump Inhibitors−Induced Mortality Risk in Hemodialysis Patients
Jonas Tadeu Cau Sertório (2019)
10.1007/s40261-017-0519-y
Acid-Suppressive Therapy and Risk of Infections: Pros and Cons
L. Fisher (2017)
10.1016/j.ejim.2016.10.007
The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal.
V. Savarino (2017)
10.17235/reed.2018.5468/2018
Appropriateness of the use of proton pump inhibitors in the Emergency Department of a Spanish university hospital.
Beatriz Granero-Melcon (2018)
10.1159/000487963
Increased Risk of Spontaneous Bacterial Peritonitis in Cirrhotic Patients Using Proton Pump Inhibitors
Abdel-Naser Y Elzouki (2018)
10.4254/wjh.v11.i6.522
Proton pump inhibitors increase the severity of hepatic encephalopathy in cirrhotic patients
Matthew Fasullo (2019)
10.1111/jgs.16117
Low-Value Proton Pump Inhibitor Prescriptions Among Older Adults at a Large Academic Health System.
John N. Mafi (2019)
10.1017/ice.2014.39
Comorbidities, Exposure to Medications, and the Risk of Community-Acquired Clostridium difficile Infection: a systematic review and meta-analysis.
Luis Furuya-Kanamori (2015)
10.11005/jbm.2018.25.3.141
Proton-pump Inhibitor Use and Fracture Risk: An Updated Systematic Review and Meta-analysis
Y. Nassar (2018)
10.17235/reed.2015.3882/2015
Reasons for initiation of proton pump inhibitor therapy for hospitalised patients and its impact on outpatient prescription in primary care.
Elena Villamañán (2015)
10.1007/s11684-018-0630-3
In silico design of novel proton-pump inhibitors with reduced adverse effects
X. Li (2018)
Study on Appropriateness and Cost Comparison of Prescription of Proton Pump Inhibitors at a Tertiary Care Hospital
Susan Thomas Pheba (2016)
10.22159/ijap.2018.v10s1.79
Proton-pump inhibitor use and potential drug interactions in outpatients
Nadia Farhanah Syafhan (2018)
STUDY AND ASSESSMENT OF APPROPRIATENESS IN THE USAGE OF PROTON PUMP INHIBITORS IN A TERTIARY CARE TEACHING HOSPITAL IN SOUTH INDIA
Blesson Mathew (2015)
10.1111/bcp.14197
Impact of a multidisciplinary quality improvement initiative to reduce inappropriate usage of stress ulcer prophylaxis in hospitalized patients
Y. J. Choi (2019)
Semantic Scholar Logo Some data provided by SemanticScholar